Burkholderia cepacia complex

Taxonomy

Yabuuchi et al. 1993

• ATCC 25416{{efn|Also: CCUG 12691 and 13226; CFBP 2227; CIP 80.24; DSM 7288; HAMBI 1976; ICMP 5796; JCM 5964; LMG 1222; NBRC 14074; NCCB 76047; NCPPB 2993; NCTC 10743; NRRL B-14810}}
• Pseudomonas multivorans Stanier et al. 1966
• Pseudomonas cepacia (ex Burkholder 1950) Palleroni and Holmes 1981
• Pseudomonas kingii Jonsson 1970 The group includes B. cepacia, B. multivorans, B. cenocepacia, B. vietnamiensis, B. stabilis, B. ambifaria, B. dolosa, B. anthina, B. pyrrocinia and B. ubonensis, among other species.

Occurrence

BCC is resistant to a number of common disinfectants, specifically povidone-iodine, triclosan, chlorohexidine, cetylpyridinium chloride, and quaternary ammoniums such as benzalkonium chloride. Concentrations used as preservatives in water-based pharmaceutical products are often not enough to kill BCC or even stop it from proliferating. Even higher-concentration versions of these biocides intended for disinfection, such as povidone-iodine solution for wound dressing and benzonium chloride wipes, may harbor live BCC if not sterilized using another method.

Burkholderia cepacia is also found in marine environments (marine sponges) and some strains of Burkholderia cepacia can tolerate high salinity. S.I. Paul et al. (2021) isolated and biochemically characterized salt tolerant strains of Burkholderia cepacia from marine sponges of Saint Martin's Island of the Bay of Bengal, Bangladesh.

Human infection

Pathogenesis

BCC organisms are typically found in water and soil and can survive for prolonged periods in moist environments. They show a relatively poor virulence. Virulence factors include adherence to plastic surfaces (including those of medical devices) and production of several enzymes such as elastase and gelatinase. Also relevant might be their ability to survive attacks from neutrophils.

Person-to-person spread has been documented; as a result, many hospitals, clinics, and camps have enacted strict isolation precautions for those infected with BCC. Infected individuals are often treated in a separate area from uninfected patients to limit spread, since BCC infection can lead to a rapid decline in lung function and result in death.

BCC infection is a contraindication for lung transplantation and cystic fibrosis patients infected with BCC may be excluded from transplantation due to the increased mortality. Additionally, lung transplant recipients infected with B. cenocepacia are six times more likely to die within a year of transplantation than those infected with other BCC organisms.

Diagnosis

Diagnosis of BCC involves culturing the bacteria from clinical specimens, such as sputum or blood. BCC organisms are naturally resistant to many common antibiotics, including aminoglycosides and polymyxin B. and this fact is exploited in the identification of the organism. The organism is usually cultured in Burkholderia cepacia agar (BC agar), which contains crystal violet and bile salts to inhibit the growth of Gram-positive cocci, and ticarcillin and polymyxin B to inhibit the growth of other Gram-negative bacilli. It also contains phenol red pH indicator which turns pink when it reacts with alkaline byproducts generated by the bacteria when it grows.

Alternatively, oxidation-fermentation polymyxin-bacitracin-lactose (OFPBL) agar can be used. OFPBL contains polymyxin (which kills most Gram-negative bacteria, including Pseudomonas aeruginosa) and bacitracin (which kills most Gram-positive bacteria and Neisseria species). It also contains lactose, and organisms such as BCC that do not ferment lactose turn the pH indicator yellow, which helps to distinguish it from other organisms that may grow on OFPBL agar, such as Candida species, Pseudomonas fluorescens, and Stenotrophomonas species.

Treatment

Treatment typically includes multiple antibiotics and may include ceftazidime, minocycline, piperacillin, meropenem, chloramphenicol, and trimethoprim/sulfamethoxazole(co-trimoxazole). Although co-trimoxazole has been generally considered the drug of choice for B. cepacia infections, ceftazidime, minocycline, piperacillin, and meropenem are considered to be viable alternative options in cases where co-trimoxazole cannot be administered because of hypersensitivity reactions, intolerance, or resistance. Newer beta-lactam / beta-lactamase combinations like ceftazidime-avibactam or ceftolozane-tazobactam can also be effective. BCC intrinsically resistant to colistin and usually resistant to aminoglycosides.

In people with cystic fibrosis, evidence is insufficient about the effectiveness of long-term antibiotic treatment with continuous inhaled aztreonam lysine (AZLI) in terms of lung function or chest infections.

History

B. cepacia was discovered by Walter Burkholder in 1949 as the cause of onion skin rot, and first described as a human pathogen in the 1950s. It was first isolated in patients with cystic fibrosis (CF) in 1977, when it was known as Pseudomonas cepacia. In the 1980s, outbreaks of B. cepacia in individuals with CF were associated with a 35% death rate. B. cepacia has a large genome, containing twice the amount of genetic material as E. coli.

On 8 August 2025 a voluntary recall was issued by DermaRite Industries for certain of its hand soap products contaminated with the bacteria complex (exact species not specified); risk of sepsis in the immunocompromised was particularly noted.

References

References

1. Lipuma J. (2005). "Update on the ''Burkholderia cepacia'' complex". Curr Opin Pulm Med.
2. (2005). "The multifarious, multireplicon ''Burkholderia cepacia'' complex". Nat Rev Microbiol.
3. "ATCC: Bacteria Collection".
4. "Specimen Details".
5. (17 June 2020). "Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.". Clinical Microbiology Reviews.
6. "OTC DRUG Recall of Benzalkonium Chloride Antiseptic Wipes".
7. (March 2009). "Biocide susceptibility of the Burkholderia cepacia complex". The Journal of Antimicrobial Chemotherapy.
8. (December 2021). "Identification of marine sponge-associated bacteria of the Saint Martin's island of the Bay of Bengal emphasizing on the prevention of motile Aeromonas septicemia in Labeo rohita". Aquaculture.
9. (2009). "Oxford Handbook of Infectious Diseases and Microbiology". Oxford University Press.
10. (2020). "Mandell, Douglas, and Bennett's principles and practice of infectious diseases".
11. (2001). "Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex: Survival Linked to Genomovar Type". American Journal of Respiratory and Critical Care Medicine.
12. (2008). "Survival After Lung Transplantation of Cystic Fibrosis Patients Infected with Burkholderia cepacia Complex". American Journal of Transplantation.
13. McGowan J. (2006). "Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum". Am J Infect Control.
14. Becton, Dickinson and Company. (2003). "BD Difco and BD BBL Manual: Manual of Microbiological Culture Media". Becton Dickinson.
15. (1997). "Remel Technical Manual". Remel.
16. (2020). "Mandell, Douglas, and Bennett's principles and practice of infectious diseases".
17. (May 2009). "Therapeutic options for ''Burkholderia cepacia'' infections beyond co-trimoxazole: a systematic review of the clinical evidence". Int. J. Antimicrob. Agents.
18. (2020). "The Sanford guide to antimicrobial therapy 2020".
19. (2021-12-10). "Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis". The Cochrane Database of Systematic Reviews.
20. Burkholder WH. (1950). "Sour skin, a bacterial rot of onion bulbs". Phytopathology.
21. (1977). "''Pseudomonas cepacia'' in the respiratory flora of patients with cystic fibrosis". Pediatr Res.
22. Investigations, Office of Inspections and. (August 9, 2025). "DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination".
23. (August 12, 2025). "Hand soaps recalled nationwide over potential for 'serious and life-threatening infections'".